Underneath the Arches, no. 61, October 24, 1968

Underneath the Arches was Grand Valley State\u27s faculty and staff newsletter, published from 1963 to 1971. It was a precursor to the Forum

Representative immunohistochemical stainings.

<p>CD31 (A, B; microvascular density), Ki-67 (C, D; cell proliferation), TUNEL (E, F; apoptosis) and VEGFR2 expression (G,H) in the therapy (left column: A, C, E, G) and in the control group (right column: B, D, F, H). Note the significant lower (p < 0.01) microvascular density, tumor cell proliferation and VEGFR2 expression and the significant higher (p < 0.01) apoptosis rate in the therapy group. Scale bar in images represents 100 μm.</p

Individual functional CEUS values.

<p>Individual functional CEUS values.</p

Line regression analysis for the correlation between CEUS parameter of VEGFR2-specific binding and immunohistochemical VEGFR2 expression.

<p>Note the significant correlation between the values of SI_8min and the number of VEGFR2 positive stained vessels (Spearman´s ρ = 0.66, p = 0.003) for the therapy and the control group.</p

Column charts of SI_10min in the therapy and control group at follow-up.

<p>Note the significant difference (p < 0.05) between the mean values of SI_10min between the therapy and the control group at the follow-up.</p

Individual immunohistochemical values.

<p>Individual immunohistochemical values.</p

Correlations between functional CEUS values and immunohistochemistry.

<p>Correlations between functional CEUS values and immunohistochemistry.</p

Influence of long CAG and age on cerebral gray matter.

<p><b>Note.</b> L, left; R, right;</p><p>*corrected P value at the set level, 0.023.</p

Individual DCE-MRI values.

<p>Individual DCE-MRI values.</p

Representative CEUS images of a rat with a subcutaneous tumor xenograft (white arrows) under treatment.

<p>Therapy group (red) and control group (blue) at baseline and follow-up. Left side: early vascular phase with BR55 as a functional imaging biomarker; right side: late phase of VEGFR2-specific binding with BR55 as a molecular imaging biomarker 8 minutes after contrast injection. Note the significant lower number of circulating microbubbles in the early vascular phase as well as the significant lower number of bound microbubbles in the late phase at follow-up in the therapy group, compared to baseline and compared to the control group.</p